Form 4: Recursion Pharmaceuticals Director Stock Grant

Dar Zavain, a Director at Recursion Pharmaceuticals, received a stock grant under the company's Outside Director Compensation Policy.

Summary

• Dar Zavain, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 5,109 shares of Class A Common Stock on July 1, 2026.
• These shares were issued under the company's Outside Director Compensation Policy.
• The reported acquisition value was $0, indicating it was a grant rather than a purchase.
• Following this transaction, Dar Zavain beneficially owns 240,764 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine director stock grant and does not contain new financial performance data or strategic shifts.

Positives

• Director compensation aligns with company policy, ensuring alignment with shareholder interests.
• Grant of shares to a director can signal confidence in the company's future prospects.
• The director's beneficial ownership remains substantial at 240,764 shares.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a director's stock grant.

Industry Context

StockSavvy.ai notes that director stock grants are a common form of compensation in the biotechnology and pharmaceutical sectors, aiming to attract and retain experienced board members and align their interests with long-term company value creation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant is part of a pre-defined compensation policy, indicating standard director remuneration practices. Dilution is minimal given the typical nature of such grants.
• Employees: No direct impact on employees is indicated by this filing.
• Management: Reinforces the compensation structure for the board of directors.

Key Dates

Keywords

Form 4, SEC Filing, Director Compensation, Stock Grant, Recursion Pharmaceuticals, RXRX, Beneficial Ownership, Class A Common Stock